Routine use of expensive hemostatic agents during RALPN does not seem to be justified. The use of hemostatic agents (HAs) during standard robotic-assisted laparoscopic partial nephrectomy (RALPN) does ...
Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma. Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results